(Q35219373)

7 August 2017

1 reference

title

Oral direct thrombin inhibitors in clinical development (English)

1 reference

7 August 2017

D Gustafsson

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

Journal of Internal Medicine

7 August 2017

published in

1 reference

7 August 2017

volume

254

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

322-334

1 reference

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Monitoring of anticoagulant effects of direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Melagatran attenuates fibrin and platelet deposition in a porcine coronary aartery over-stretch injury model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Antithrombotic therapy in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Warfarin, aspirin, or both after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Delayed elimination of enoxaparine in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Warfarin induced skin necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

Prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01225.X

10.1046/J.1365-2796.2003.01225.X

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference